Utilisateur:Xd

Un article de Wikipédia, l'encyclopédie libre.

==Présentation==

  • Prénom : Xavier
  • Né le 09 Avril 1970 à Clermont ferrand Auvergne Puy-de-Dôme
  • Début sur Wikipédia en Juillet 2005
Wikipédia:Babel
fr
Ma langue maternelle
est le français.
en-2
I am able to contribute with an intermediate level of English.

==Professionnellement==

  • MD [médecin cancérologue] (1999)
  • PhD [Thésard en biologie] (2008)
  • Principales publications:


  • [1] O Bay, B Choufi, C Pomel, J Dauplat, X Durando, O Tournilhac, P Travade, R Plagne and D Blaise. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplantation (2000) 25, 681-382
  • [2] H. Curé, X. Durando. Les tumeurs gliales sus-tentorielles de l’adulte. In : J.-F.Morère, F.Mornex, M.Piccard, J.M.Nabholtz, eds. Thérapeutique du cancer. France Springer-Verlag France. 2000
  • [3] X.Durando in The BRCA1 Exon 13 Duplication Screening Group. The Exon 13 Duplication in the BRCA1 gene is a founder mutation present in geographically Diverse populations. Am J Hum Genet 67:207-212, 2000
  • [4] X. Durando, H. Curé. Nausée et vomissement : aspects cliniques et thérapeutiques dans les cancers gynécologiques In : Nausées et vomissements en chimiothérapie oncologique. eds.John Libbey Eurotext. 2002
  • [5] Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO.High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant. 2003 Apr;31(7):559-64
  • [6] Penault-Llorca F, Durando X, Bay JO. Prognostic value of epidermal growth factor receptor. Bull Cancer. 2003 Nov;90 Spec No:S192-6
  • [7] Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC, Chollet P. Methionine dependency and cancer treatment. Cancer Treat Rev. 2003 Dec;29(6):489-99
  • [8] Durando X, Cure H. Management of a patient with cancer during all stages of disease. Symptomatic treatment. Modalities of surveillance. Psychological, ethical and social problem Rev Prat. 2004 Nov 15;54(17):1949-55
  • [9] Durando, Xavier; Thivat, Emilie; Demidem, Aicha; Madelmont, Jean-Claude; Chollet, Philippe. New Approches in Advanced Melanoma Treated by Nitrosourea. Journal of Immunotherapy. 27(6):S52-S53, November/December 2004
  • [10] Thivat E, Durando X, D'Incan M, Cure H, Mouret-Reynier MA, Madelmont JC, Souteyrand P, Chollet P. Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.Anticancer Drugs. 2005 Oct;16(9):1003-7
  • [11] Durando X, Thivat E, D'Incan M, Sinsard A, Madelmont JC, Chollet P. Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. BMC Cancer. 2005 Nov 15;5:147
  • [12] Xavier Durando, Jean Jacques Lemaire, Hervé Curé, Jean-Jacques Mazeron. Juin 2006. Les tumeurs intracrâniennes. Université Médicale Virtuelle Francophone Polycopié national de cancérologie. Sous l'égide du Collège National des Enseignants de Cancérologie, coordination : Pr M. Schneider, Pr D. Cowen, Pr G. Kantor, Pr S. Culine.(http://cancero.unice.fr/sitelocal/disciplines/niveaudiscipline/cancerologie/numlecon146/leconimprim.pdf)
  • [13] Abrial C, Mouret-Reynier MA, Cure H, Feillel V, Leheurteur M, Lemery S, Le Bouedec G, Durando X, Dauplat J, Chollet P. Neoadjuvant endocrine therapy in breast cancer. Breast. 2006 Feb;15(1):9-19
  • [14] Abrial C, Leheurteur M, Cabrespine A, Mouret-Reynier MA, Durando X, Ferriere JP, Kwiatkowski F, Penault-Llorca F, Cure H, Chollet P. Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncol Res. 2006;15(9):431-9
  • [15] Durando X, Thivat E, Roche H, Bay JO, Lemaire JJ, Verrelle P, Lentz MA, Chazal J, Cure H, Chollet P. Cystemustine in recurrent high grade glioma. J Neurooncol. 2006 Mar 31
  • [16] Gimbergues P, Dauplat MM, Cayre A, Durando X, Le Bouedec G, Finat-Duclos F, Portefaix G, Kwiatkowski F, Dauplat J, Penault-Llorca F, Tchirkov A. Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category. Eur J Surg Oncol. 2006 Oct 26
  • [17] Chollet P, Abrial C, Tacca O, Mouret-Reynier MA, Leheurteur M, Durando X, Cure H. R. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer. 2006 Oct;7(4):336-8
  • [18] B.Nayl, X.Durando, H.Curé. Ovarian cancer, consolidation or maintenance : from concept to therapy. Oncologie. 2006 8: 152-159
  • [19] Mouret-Reynier MA, Abrial C, Leheurteur M, Durando X, Van Praagh I, Gimbergues P, Achard JL, Ferriere JP, Cure H, Chollet P. Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer. Bull Cancer. 2006 Nov 1;93(11):1121-9
  • [20] Bay JO, Linassier C, Biron P, Durando X, Verrelle P, Kwiatkowski F, Rosti G, Demirer T for the EMBT solid tumors working party. Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? an EBMT retrospective study. Int J Cancer. 2007 Jan 17;120(8):1782-1786
  • [21] Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Cure H, Chollet P. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 2007 Jun;12(6):636-43
  • [22] Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Leheurteur M, Gimbergues P, Tortochaux J, Cure H, Chollet P. Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. Oncologist. 2007 Apr;12(4):390-6
  • [23] H. Cure, H. Devaud, X. Durando and O. Bézy. Intérêt d'une approche multidisciplinaire en psycho-oncologie des personnes âgées. Annales Médico-psychologiques, revue psychiatrique, Volume 165, Issue 3, April 2007, Pages 220-224
  • [24] Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E, Guenin S, D'Incan M, Vasson MP, Chollet P. A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2779-83
  • [25] Durando X, Thivat E, Gilliot O, Irthum B, Verrelle P, Vincent C, Bay JO. Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest. 2007 Sep;25(6):470-5.
  • [26] I. Toledano, T. Khalil, O. Gilliot, X. Durando, J.-O. Bay, J. Tortochaux, N. Bourry, J.-L. Kémény, M. Lapeyre and P. Verrelle. Association concomitante de radiothérapie témozolomide chez les patients atteints de glioblastome : résultats d'une étude monocentrique rétrospective. Cancer/Radiothérapie. Volume 11, Issues 6-7, November 2007, Pages 425-426
  • [27] Montmayeur G, Thivat E, Gimbergues P, Dib M, Leheurteur M, Curé H, Chollet P, Durando X. Peritoneal mesothelioma: Long survival with intraperitoneal chemotherapy, lanreotide and mucolytics. Gastroenterol Clin Biol. 2008 Mar 17
  • [28] Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F, Mouret-Reynier MA, Kwiatkowski F, Maublant J, Tchirkov A, Dauplat J.Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008 May;15(5):1316-21
  • [29] Durando X, Thivat E, Gimbergues P, Cellarier E, Abrial C, Dib M, Tacca O, Chollet P. Methionine dependency of cancer cells: a new therapeutic approach? Bull Cancer. 2008 Jan 1;95(1):69-76
  • [30] Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorc F.A New Prognostic Classification After Primary Chemotherapy for Breast Cancer: Residual Disease in Breast and Nodes (RDBN).Cancer J. 2008 March/April;14(2):128-132)
  • [31] Durando X, Thivat E , Farges MC, Cellarier E, D'Incan M, Demidem A, Vasson MP, Barthomeuf C, Chollet P. Optimal methionine free diet duration for nitrosourea treatment : a phase I clinical trial. Nutr Cancer, 2007 (in Press)
  • [32] M-C. Farges, E. Thivat, X. Durando, E. Cellarier, A. Léger-Enreille, S. Jouvency, P. Chollet, M-P. Vasson. Effect of a short-term methionine-free diet on amino acid profiles in patients with advanced melanoma or glioma. Br J Cancer, 2008 (in Press)
  • [33] Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurteur M, Durando X, Achard JL, Gimbergues P, Chollet P. Comparison of the prognostic significance of Chevallier’s and Sataloff’s pathological classifications after neoadjuvant chemotherapy of operable breast cancer. Human Pathology. (Soumis)